~~<i id='467A0008F0'><strike id='467A0008F0'><tt id='467A0008F0'><pre id='467A0008F0'></pre></tt></strike></i>~~

Home» comprehensive» leisure time

leisure time

author：hotspot 2025-09-29 04:14:15 Page View：1929

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Researchers tackle phage therapy hurdles for wider adoption
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

focus

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Type 2 diabetes prevention programs work at large scale: study

LeonNeal/GettyImagesLONDON—Clinicaltrialshaveshownthatlifestyleprograms—whichincludediet,exercise,an

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

New study raises questions about niacin and heart health

MattRourke/APNiacin,orvitaminB3,haslongbeenaU.S.publichealthdarlingtothepointthatitisadded,bylaw,toc